Lack of association of C-Met-N375S sequence variant with lung cancer susceptibility and prognosis

International Journal of Medical Sciences

Volumn 10, Issue 8, 2013, Pages 988-994

  Shieh, Jiunn Min ^a,b   Tang, Yen An ^c   Yang, Tsung Han ^c   Chen, Chih Yi ^d   Hsu, Han Shui ^e   Tan, Yi Hung Carol ^c   Salgia, Ravi ^f   Wang, Yi Ching ^c  

^a CHI MEI MEDICAL CENTER   (Taiwan)

^b CHANG JUNG CHRISTIAN UNIVERSITY   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^d CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e NATIONAL YANG MING UNIVERSITY   (Taiwan)

^f UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

C Met; Cancer risk; Lung cancer; N375S; Prognosis

Indexed keywords

SCATTER FACTOR RECEPTOR;

AGED; ARTICLE; C MET GENE; CANCER PROGNOSIS; CANCER RISK; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CELL DEATH; CONTROLLED STUDY; DNA SEQUENCE; DOWN REGULATION; FEMALE; GENE EXPRESSION REGULATION; GENE FREQUENCY; GENE FUNCTION; GENE LOCATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; SURVIVAL TIME; TAIWAN; WILD TYPE;

EID: 84879294666     PISSN: 14491907     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijms.5944     Document Type: Article

References (16)

1. Department of Health: The Executive Yuan RoC. General Health Statistics, 2010. In: Health and Vital Statistics, Republic of China. R. O. C. Press, Taipei, pp 86-108, 2011.
2. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010; 60: 277-300.
3. Blumenschein GR, Jr., Mills GB, Gonzalez-Angulo AM. Targeting the hepatocyte growth factor-cMET axis in cancer therapy. J Clin Oncol. 2012; 30: 3287-3296.
4. Cipriani NA, Abidoye OO, Vokes E, et al. MET as a target for treatment of chest tumors. Lung Cancer. 2009; 63: 169-179.
5. Liu Y. The human hepatocyte growth factor receptor gene: complete structural organization and promoter characterization. Gene. 1998; 215: 159-169.
6. Krishnaswamy S, Kanteti R, Duke-Cohan JS, et al. Ethnic differences and functional analysis of MET mutations in lung cancer. Clin Cancer Res. 2009; 15: 5714-5723.
7. Tengs T, Lee JC, Paez JG, et al. A transforming MET mutation discovered in non-small cell lung cancer using microarray-based resequencing. Cancer Lett. 2006; 239: 227-233.
8. Ma PC, Jagadeeswaran R, Jagadeesh S, et al. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res. 2005; 65: 1479-1488.
9. Ma PC, Kijima T, Maulik G, et al. c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res. 2003; 63: 6272-6281.
10. Dulak AM, Gubish CT, Stabile LP, et al. HGF-independent potentiation of EGFR action by c-Met. Oncogene. 2011; 30: 3625-3635.
11. Lawrence RE, Salgia R. MET molecular mechanisms and therapies in lung cancer. Cell Adh Migr. 2010; 4: 146-152.
12. Berthou S, Aebersold DM, Schmidt LS, et al. The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants. Oncogene. 2004; 23: 5387-5393.
13. Salgia R, Hensing T, Campbell N, et al. Personalized treatment of lung cancer. Semin Oncol. 2011; 38: 274-283.
14. Stabile LP, Rothstein ME, Keohavong P, et al. Targeting of Both the c-Met and EGFR Pathways Results in Additive Inhibition of Lung Tumorigenesis in Transgenic Mice. Cancers (Basel). 2010; 2: 2153-2170.
15. Tang Z, Du R, Jiang S, et al. Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer. Br J Cancer. 2008; 99: 911-922.
16. Yap TA, Olmos D, Brunetto AT, et al. Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies. J Clin Oncol. 2011; 29: 1271-1279.